Nevertheless, on comparing the results with the general population corresponding to the same age range, it is seen that despite the great advance represented by the introduction of trastuzumab, a total of 98,973 years will still be lost due to HER2+ BC with follow-up of the cohorts to the year 2035. The gene discussed is ERBB2; the disease is breast cancer.